The vaccine is very effective in preventing...

Pneumococcus cause infectious diseases in children and adults, including invasive infections (eg, bacteremia and meningitis) and respiratory tract infections (eg pneumonia and otitis media). (1.2)

pneumococcus is responsible for about 40,000 people and 500,000 cases of pneumonia annually in the United States. There are over 90 serotypes

pneumococcus. Serotypes responsible for disease depends on age

and geographic location. Children 6 years, 7 serotypes (4, 6B, 9V, 18C, 19F and 23F) accounted for 80% of invasive disease >> << to 100% of all strains that are highly resistant to penicillin treatment. (3.4)

In adults, risk factors for pneumococcal infection include chronic cardiovascular disease, chronic lung disease, diabetes, alcoholism, asthma, treatment with corticosteroids. The highest risk situations associated with immunosuppression, including those that are disease-related (eg, multiple myeloma or iatrogenic, aspleniya [sickle cell disease], neutropenia and humoral immune deficiency). Bacterial polysaccharides causing antibodies in children of T cells and independent mechanism of immune responses to polysaccharide antigens such as pneumococcus, usually poor children under 2 years. Active immunization of children 2 years old need more injections of vaccine, prepared strattera prescription from purified polysaccharides related to immunogenic carrier (

Corynebacterium diphtheria strain C7 protein). Recommended vaccines for children from 2 years (Prevnar) contains 7 serotypes mentioned above, and injected into 4 doses. The vaccine is very effective in preventing invasive disease in children, reported the effectiveness of 88% to 100%. Active immunization of adults and children 2 years of conducted nekon'yuhirovannoy polysaccharide vaccines, which contain additional serotypes (eg, Pneumovax or CGP-Imune 23). Pneumovax and CGP-Imune 23 containing 23 different purified polysaccharides of serotypes, which make up 90% on selected blood and 85% of strains from normally sterile body fluids. Protective antibody levels develop in nonimmunocompromised adults and older children approximately 3 weeks after immunization and overall efficiency of 60% to 80% for protection against pneumonia and bacteremia. Serotype-specific antibodies persist for 10 years after immunization. .